S. Le-taux-de, 12 et 24 mois est respectivement de 91%9% (cf. courbe ci-dessous)On compte 39 rechutes sur les 56 rémissions 1 Adult Acute Myeloid Leukemia Treatment (PDQ®) National Cancer Institute, pp.4-18, 2014.

A. Aleem, F. Anjum, F. Algahtani, Z. Iqbal, K. Alsaleh et al., Clofarabine in the Treatment of Elderly Patients with Acute Myeloid Leukemia, Asian Pacific Journal of Cancer Prevention, vol.14, issue.2, pp.1089-92, 2013.
DOI : 10.7314/APJCP.2013.14.2.1089

S. Amadori, S. Suciu, R. Willemze, F. Mandelli, D. Selleslag et al., Sequential Administration of Gemtuzumab Ozogamicin and Conventional Chemotherapy as First Line Therapy in Elderly Patients with Acute Myeloid Leukemia: A Phase II Study (AML-15) of the EORTC and GIMEMA Leukemia Groups, Haematologica, vol.89, issue.8, pp.950-56, 2004.

J. E. Anderson, J. Kenneth, C. L. Kopecky, D. Willman, M. R. Head et al., Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study, Blood, vol.100, issue.12, pp.3869-76, 2002.
DOI : 10.1182/blood-2001-12-0354

B. Luna, E. , L. I. Omaña-guzmán, L. Ortiz-hernández, S. A. Ñamendis-silva et al., [Nutritional status in patients first hospital admissions service hematology National Cancer Institute], Nutrición Hospitalaria, vol.28, issue.4, pp.1259-65, 2013.

B. Behringer, J. A. Pitako, R. Kunzmann, C. Schmoor, D. Behringer et al., Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study, Annals of Hematology, vol.82, issue.7, pp.381-89, 2003.
DOI : 10.1007/s00277-003-0650-0

R. Boulahssass, F. Auben, S. Gonfrier, J. M. Turpin, I. Bereder et al., Geriatric interventions in the management of older patients with cancer, European Geriatric Medicine, vol.4, pp.92-92, 2013.
DOI : 10.1016/j.eurger.2013.07.300

R. Boulahssass, E. Chamorey, I. Bereder, V. Mari, H. Jaoua et al., Impact de l'évaluation gériatrique standardisée en oncologie: analyse rétrospective monocentrique chez 59 patients âgés atteints de cancer, pp.41-48, 2010.

R. Boulahssass, V. Mari, S. Gonfrier, F. Auben, A. Abakar-mahamat et al., Early death in older patients with cancer: risk factors of worse outcomes?, Journal of Geriatric Oncology, vol.4, pp.85-85, 2013.
DOI : 10.1016/j.jgo.2013.09.142

J. M. Brandwein, M. Geddes, J. Kassis, K. Andrea, B. Kew et al., Treatment of Older Patients with Acute Myeloid Leukemia (AML): A Canadian Consensus, American Journal of Blood Research, vol.3, issue.2, pp.141-64, 2013.

A. Candoni, G. Martinelli, E. Toffoletti, A. Chiarvesio, M. Tiribelli et al., Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years, Leukemia Research, vol.32, issue.12, pp.1800-1808, 2008.
DOI : 10.1016/j.leukres.2008.05.011

A. F. Cashen, H. Devine, and J. Dipersio, Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine, American Journal of Hematology, vol.19, issue.7, pp.543-588, 2006.
DOI : 10.1002/ajh.20626

B. D. Cheson, P. A. Cassileth, D. R. Head, C. A. Schiffer, J. M. Bennett et al., Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia., Journal of Clinical Oncology, vol.8, issue.5, pp.813-832, 1990.
DOI : 10.1200/JCO.1990.8.5.813

. Study, The Lancet, pp.354-62, 2013.

A. Couderc, S. Ciuca, and N. Mounier, Leucémie aiguë chez le sujet âgé. Interêt et discussion de la prise en charge, pp.3-4, 2011.

H. Dombret, E. Raffoux, and C. Gardin, New insights in the management of elderly patients with acute myeloid leukemia, Current Opinion in Oncology, vol.21, issue.6, pp.589-93, 2009.
DOI : 10.1097/CCO.0b013e3283313e10

F. Patrice, F. Magali, D. Benjamin, and G. Marion, « Etude d'image : le CHU de Grenoble vu par les médecins généraliste, pp.4-2014

L. Fratino, M. Rupolo, M. Mazzuccato, M. Berretta, A. Lleshi et al., Autologus Stem Cell Transplatation as a Care Option in Elderly Patients. A Review, Anti-Cancer Agents in Medicinal Chemistry, vol.13, issue.9, pp.1419-1448, 2013.
DOI : 10.2174/18715206113136660357

C. Gardin, P. Turlure, T. Fagot, X. Thomas, C. Terre et al., Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial, Blood, vol.109, issue.12, pp.5129-5164, 2007.
DOI : 10.1182/blood-2007-02-069666

URL : https://hal.archives-ouvertes.fr/hal-00453273

F. J. Giles, F. Gautam-borthakur, S. Ravandi, S. Faderl, D. Verstovsek et al., The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60???years of age receiving induction therapy for acute myeloid leukaemia., British Journal of Haematology, vol.106, issue.4, pp.624-651, 2007.
DOI : 10.1111/j.1365-2141.2006.06476.x

A. H. Goldstone, A. K. Burnett, K. Wheatley, A. G. Smith, R. E. Hutchinson et al., Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial, Blood, vol.98, issue.5, pp.1302-1313, 2001.
DOI : 10.1182/blood.V98.5.1302

V. Gupta, K. Chun, Q. Yi, M. Minden, A. Schuh et al., Disease biology rather than age is the most important determinant of survival of patients ??? 60 years with acute myeloid leukemia treated with uniform intensive therapy, Cancer, vol.84, issue.10, pp.2082-90, 2005.
DOI : 10.1002/cncr.21006

G. K. Halkett, M. Jiwa, and E. A. Lobb, Patients' perspectives on the role of their general practitioner after receiving an advanced cancer diagnosis, European Journal of Cancer Care, vol.179, issue.5, 2014.
DOI : 10.1111/ecc.12224

M. E. Hamaker, M. Mitrovic, and R. Stauder, The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy, Annals of Hematology, vol.53, issue.10, pp.1031-1071, 2014.
DOI : 10.1007/s00277-013-2001-0

J. C. Hernandez-boluda, J. Sierra, J. Esteve, B. Nomdedeu, and E. Montserrat, Treatment of Elderly Patients with AML: Results of an Individualized Approach, Haematologica, vol.83, issue.1, pp.34-39, 1998.

P. Hirsch, G. Qassa, C. Marzac, R. Tang, J. Perrot et al., Acute Myeloid Leukemia in Patients Older than 75: Prognostic Impact of FLT3-ITD and NPM1 Mutations, Leukemia & Lymphoma, pp.1-4, 2014.

X. Hu, F. Liu, C. Zheng, L. Li, C. Liu et al., Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy, Chinese Journal of Integrative Medicine, vol.17, issue.3, pp.193-97, 2009.
DOI : 10.1007/s11655-009-0193-x

R. Itzykson, C. Gardin, C. Pautas, X. Thomas, P. Turlure et al., Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria, Haematologica, vol.96, issue.6, pp.837-881, 2011.
DOI : 10.3324/haematol.2010.036921

P. Iversen, E. Ole, B. Ukrainchenko, K. Afanasyev, A. Hulbekkmo et al., Impaired nutritional status during intensive chemotherapy in Russian and Norwegian cohorts with acute myeloid leukemia, Leukemia & Lymphoma, vol.35, issue.10, pp.1916-2410, 1080.
DOI : 10.1038/sj.leu.2404440

K. Jackson, G. Kennedy, P. Mollee, P. Marlton, and K. Morris, Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients, Asia-Pacific Journal of Clinical Oncology, vol.121, issue.Suppl 1, 2014.
DOI : 10.1111/ajco.12188

P. R. Johnson and J. A. Liu-yin, Prognostic Factors in Elderly Patients with Acute Myeloid Leukaemia, Leukemia & Lymphoma, vol.4, issue.1, pp.51-56, 1994.
DOI : 10.1001/archinte.1983.00350010039008

G. Juliusson, Older Patients With Acute Myeloid Leukemia Benefit From Intensive Chemotherapy: An Update From the Swedish Acute Leukemia Registry, Clinical Lymphoma Myeloma and Leukemia, vol.11, pp.54-59, 2011.
DOI : 10.1016/j.clml.2011.02.003

G. Juliusson, P. Antunovic, A. Derolf, S. Lehmann, L. Möllgård et al., Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry, Blood, vol.113, issue.18, pp.4179-87, 2009.
DOI : 10.1182/blood-2008-07-172007

T. Kadia, S. O. Kashani, J. Brien, E. Cortes, . Jabbour et al., Evaluation of Efficacy and Mortality in Elderly Patients (pts) (70 Years [yrs] or Older) with Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC). --Kadia et Al Meeting Abstracts, p.6529, 2014.

H. Kantarjian, S. Faderl, G. Garcia-manero, S. Luger, P. Venugopal et al., Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study, The Lancet Oncology, vol.13, issue.11, pp.1096-1104, 2012.
DOI : 10.1016/S1470-2045(12)70436-9

H. Kantarjian, G. Garcia-manero, S. O. Brien, S. Faderl, F. Ravandi et al., Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome, Journal of Clinical Oncology, vol.28, issue.2, pp.285-91, 2010.
DOI : 10.1200/JCO.2009.25.0209

H. M. Kantarjian, G. Xavier, A. Thomas, A. Dmoszynska, G. Wierzbowska et al., Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.30, issue.21, pp.2670-77, 2012.
DOI : 10.1200/JCO.2011.38.9429

H. Kantarjian, S. O. Brien, J. Cortes, F. Giles, S. Faderl et al., Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome:, Cancer, vol.162, issue.5, pp.1090-98, 2006.
DOI : 10.1002/cncr.21723

H. Kantarjian, F. Ravandi, S. O. Brien, J. Cortes, S. Faderl et al., Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia, Blood, vol.116, issue.22, pp.4422-4451, 2010.
DOI : 10.1182/blood-2010-03-276485

G. M. Keating, Azacitidine, Drugs, vol.28, issue.23, pp.1111-1147, 2012.
DOI : 10.2165/11209430-000000000-00000

M. A. Kharfan-dabaja, C. Julio, D. Chavez, W. Yu, E. I. Zhu et al., Severe Hypoalbuminemia at Day 90 Predicts Worse Nonrelapse Mortality and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome, Biology of Blood and Marrow Transplantation, vol.17, issue.3, pp.384-93, 2011.
DOI : 10.1016/j.bbmt.2010.07.011

H. D. Klepin, A. M. Geiger, J. A. Tooze, S. B. Kritchevsky, J. D. Williamson et al., Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia, Blood, vol.121, issue.21, pp.4287-94, 2013.
DOI : 10.1182/blood-2012-12-471680

U. Krug, C. Röllig, A. Koschmieder, A. Heinecke, M. C. Sauerland et al., Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes, The Lancet, vol.376, issue.9757, pp.2000-2008, 2010.
DOI : 10.1016/S0140-6736(10)62105-8

R. Latagliata, V. Bongarzoni, I. Carmosino, A. Mengarelli, M. Breccia et al., Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon, Annals of Oncology, vol.17, issue.2, pp.281-85, 2006.
DOI : 10.1093/annonc/mdj112

C. P. Leith, J. Kenneth, J. Kopecky, T. Godwin, M. L. Mcconnell et al., Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study, Blood, vol.89, issue.9, pp.3323-3352, 1997.

R. Liersch, C. Müller-tidow, W. E. Berdel, and U. Krug, Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use, British Journal of Haematology, vol.53, issue.1, pp.17-38, 2014.
DOI : 10.1111/bjh.12750

M. Y. Lim and K. Jamieson, Profile of Sapacitabine: Potential for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients, Clinical Interventions in Aging, vol.9, pp.753-62, 2014.

A. Lindman, H. Brygger-rasmussen, and N. F. Andersen, Food caregivers influence on nutritional intake among admitted haematological cancer patients ??? A prospective study, European Journal of Oncology Nursing, vol.17, issue.6, pp.827-861, 2013.
DOI : 10.1016/j.ejon.2013.06.010

B. Löwenberg, G. J. Ossenkoppele, W. Van-putten, H. C. Schouten, C. Graux et al., High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia, New England Journal of Medicine, vol.361, issue.13, pp.1235-4810, 1056.
DOI : 10.1056/NEJMoa0901409

B. Löwenberg, 8 Treatment of the elderly patient with acute myeloid leukaemia, Bailli??re's Clinical Haematology, vol.9, issue.1, pp.147-59, 1996.
DOI : 10.1016/S0950-3536(96)80041-2

B. Löwenberg, R. Zittoun, H. Kerkhofs, U. Jehn, J. Abels et al., On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group., Journal of Clinical Oncology, vol.7, issue.9, pp.1268-74, 1989.
DOI : 10.1200/JCO.1989.7.9.1268

M. Lübbert, B. H. Rüter, R. Claus, C. Schmoor, M. Schmid et al., A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy, Haematologica, vol.97, issue.3, pp.393-401, 2012.
DOI : 10.3324/haematol.2011.048231

M. Lübbert, S. Suciu, L. Baila, B. Hans-rüter, U. Platzbecker et al., Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group, Journal of Clinical Oncology, vol.29, issue.15, pp.1987-96, 2011.
DOI : 10.1200/JCO.2010.30.9245

V. Mari, A. Fogliarini, R. Boulahssass, C. Ciais, E. Francois et al., What about the elderly cancer patients??? living wills?, Journal of Geriatric Oncology, vol.4, pp.101-102, 2013.
DOI : 10.1016/j.jgo.2013.09.179

B. L. Mcclune, J. Daniel, T. L. Weisdorf, G. Pedersen, M. S. Tunes-da-silva et al., Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome, Journal of Clinical Oncology, vol.28, issue.11, pp.1878-87, 2010.
DOI : 10.1200/JCO.2009.25.4821

M. Melchert, Managing Acute Myeloid Leukemia in the Elderly, Oncology, vol.20, issue.13, pp.1674-1682, 2006.

G. K. Mitchell, H. Letitia, S. P. Burridge, A. Colquist, and . Love, General Practitioners??? perceptions of their role in cancer care and factors which influence this role, Health & Social Care in the Community, vol.42, issue.223, pp.607-623, 2012.
DOI : 10.1111/j.1365-2524.2012.01075.x

S. Nand, J. Godwin, S. Smith, K. Barton, L. Michaelis et al., Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial, Leukemia & Lymphoma, vol.110, issue.11, pp.2141-4710, 1080.
DOI : 10.1158/0008-5472.CAN-05-2385

A. Nazha and F. Ravandi, Acute myeloid leukemia in the elderly: do we know who should be treated and how?, Leukemia & Lymphoma, vol.30, issue.1, pp.979-87, 2013.
DOI : 10.1182/blood-2009-07-235358

J. D. Nielsen, T. Palshof, J. Mainz, A. B. Jensen, and F. Olesen, Randomised controlled trial of a shared care programme for newly referred cancer patients: bridging the gap between general practice and hospital, Quality and Safety in Health Care, vol.12, issue.4, pp.263-72, 2003.
DOI : 10.1136/qhc.12.4.263

K. Oshima, W. Takahashi, Y. Asano-mori, K. Izutsu, T. Takahashi et al., Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS), Annals of Hematology, vol.8, issue.10, pp.1533-1572, 2012.
DOI : 10.1007/s00277-012-1487-1

S. Park, B. Han, J. W. Cho, S. Woo, S. Kim et al., Effect of Nutritional Status on Survival Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP, Nutrition and Cancer, vol.28, issue.2, pp.225-258, 2014.
DOI : 10.1186/1756-8722-4-34

A. Peñalva, A. San-martín, J. Rosselló, C. Pérez-portabella, A. Palacios et al., [Oral nutritional supplementation in hematologic patients], Nutrición Hospitalaria, vol.24, issue.1, pp.10-16, 2009.

F. Peyrade, L. Gastaud, and D. Re, Treatment decisions for elderly patients with haematological malignancies: a dilemma, The Lancet Oncology, vol.13, issue.8, pp.344-352, 2012.
DOI : 10.1016/S1470-2045(12)70234-6

D. A. Pollyea, E. Holbrook, B. C. Kohrt, and . Medeiros, Acute myeloid leukaemia in the elderly: a review, British Journal of Haematology, vol.3, issue.Suppl 1, pp.524-566, 2011.
DOI : 10.1111/j.1365-2141.2010.08470.x

M. Ramanathan, J. Cerny, G. Raffel, W. V. Walsh, B. Woda et al., Induction Chemotherapy with High-Dose Cytarabine and Mitoxantrone in Elderly Acute Myeloid Leukemia (AML) Patients, Journal of Clinical Oncology, vol.30, p.6569, 2012.

P. Ravasco, I. Monteiro-grillo, P. M. Vidal, and M. E. Camilo, Dietary Counseling Improves Patient Outcomes: A Prospective, Randomized, Controlled Trial in Colorectal Cancer Patients Undergoing Radiotherapy, Journal of Clinical Oncology, vol.23, issue.7, pp.1431-1469, 2005.
DOI : 10.1200/JCO.2005.02.054

E. K. Ritchie and G. J. Roboz, Levels of Care: Defining Best Supportive Care in Elderly Patients with Acute Myeloid Leukemia, Current Hematologic Malignancy Reports, vol.26, issue.35, pp.95-100, 2010.
DOI : 10.1007/s11899-010-0048-8

T. Robak and A. Wierzbowska, Current and emerging therapies for acute myeloid leukemia, Clinical Therapeutics, vol.31, issue.2, 2009.
DOI : 10.1016/j.clinthera.2009.11.017

C. Röllig, C. Thiede, M. Gramatzki, W. Aulitzky, H. Bodenstein et al., A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial, Blood, vol.116, issue.6, pp.971-78, 2010.
DOI : 10.1182/blood-2010-01-267302

C. Ro?llig, M. Bornha?user, and M. Kramer, Pre-treatment assessment in elderly AML patients: Accuracy of prognostic predictions by the treating hematologist in 343 patients from the AML 60PLUS trial ». 16th Congress of the European Hematology Association, 1018.

J. M. Rowe, D. Neuberg, W. Friedenberg, J. M. Bennett, E. Paietta et al., A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group, Blood, vol.103, issue.2, pp.479-85, 2004.
DOI : 10.1182/blood-2003-05-1686

S. Sivgin, S. Baldane, T. Ozenmis, M. Keklik, L. Kaynar et al., The Impact of Pretransplant Hypoalbuminemia on Survival in patients With Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Nutritional Problem?, Transplantation Proceedings, vol.45, issue.9, pp.3371-74, 2013.
DOI : 10.1016/j.transproceed.2013.02.144

S. Masi and . Amadori, Intensive Treatment of Patients Age 60 Years and Older with de Novo Acute Myeloid Leukemia: Analysis of Prognostic Factors, 12<2476::AID-CNCR10>3.0.CO, pp.2476-88, 1996.

R. M. Stone, T. Deborah, S. L. Berg, R. K. George, P. A. Dodge et al., Granulocyte???Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia, New England Journal of Medicine, vol.332, issue.25, pp.1671-77, 1995.
DOI : 10.1056/NEJM199506223322503

X. Thomas, S. Suciu, B. Rio, G. Leone, G. Broccia et al., Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61 70 years: results of the prospective EORTC GIMEMA AML 13 study, Haematologica, vol.92, issue.3, pp.389-96, 2007.
DOI : 10.3324/haematol.10552

S. Tiley and D. Claxton, Clofarabine in the treatment of acute myeloid leukemia in older adults, Therapeutic Advances in Hematology, vol.4, issue.1, pp.5-13, 2013.
DOI : 10.1177/2040620712461666

. Tsimberidou, H. M. Apostolia-maria, S. Kantarjian, S. O. Wen, J. Brien et al., The Prognostic Significance of Serum ??2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients, Clinical Cancer Research, vol.14, issue.3, pp.721-751, 2008.
DOI : 10.1158/1078-0432.CCR-07-2063

J. Turpin, A. Couderc, R. Boulahssass, V. Licausi, H. Vinti et al., Les hémopathies malignes du sujet âgé: à propos de 17 cas pris en charge en unité de soins de suite et de réadaptation, pp.265-71, 2013.

A. Wahlin, B. Markevärn, I. Golovleva, and M. Nilsson, Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia, British Journal of Haematology, vol.8, issue.1, pp.25-33, 2001.
DOI : 10.1016/0165-4608(93)90040-S

U. Wedding, C. Bokemeyer, and J. G. Meran, Elderly Patients with Acute Myeloid Leukaemia: Characteristics in Biology, Patients and Treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (??GHO) and the German Society for Geriatrics (DGG), Oncology Research and Treatment, vol.27, issue.1, pp.72-82, 2004.
DOI : 10.1159/000075610

U. Wedding, B. Rohrig, A. Klippstein, H. Fricke, H. Sayer et al., Impairment in functional status and survival in patients with acute myeloid leukaemia, Journal of Cancer Research and Clinical Oncology, vol.21, issue.1, pp.665-71, 2006.
DOI : 10.1007/s00432-006-0115-7

M. Wetzler, K. Mrózek, J. Kohlschmidt, H. Dombret, H. Döhner et al., Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification, Haematologica, vol.99, issue.2, pp.308-321, 2014.
DOI : 10.3324/haematol.2013.092072

K. Wheatley, C. L. Brookes, A. J. Howman, A. H. Goldstone, D. W. Milligan et al., Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials, British Journal of Haematology, vol.107, issue.5, pp.598-605, 2009.
DOI : 10.1111/j.1365-2141.2009.07663.x

R. Yamamoto, A. Yokoyama, M. Yoneda, K. Ohashi, T. Hosoda et al., Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia, Annals of Hematology, vol.93, issue.12, pp.1-2, 2014.
DOI : 10.1007/s00277-014-2119-8

. Organigramme-décisionnel-selon-pollyea, Acute myeloid leukaemia in the elderly: a review, British Journal of Haematology, vol.152, issue.5, pp.524-566, 2011.